You searched for "bladder���"
Optimisation of childhood spina bifida management – a prospective trial
Routh et al. describe a prospective trial which aims to determine the optimal urological management for children with spina bifida. The primary aim of neuropathic bladder management is to provide the patient with the best long-term quality of life with...
Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for SCC
Squamous cell carcinoma (SCC) of the bladder is more commonly seen in Egypt due to schistosomiasis (bilharziasis) and accounts for 2% to 5% of all bladder tumours. Schistosomiasis is found in the bladder vasculature and leads to chronic inflammation causing...
BCG maintenance therapy not superior to induction alone
With the ongoing shortage of BCG remaining an issue for urologists in the UK and further afield, this topical paper presented the results of the CUETO study evaluating the outcome of a modified three-year BCG maintenance regimen versus induction therapy...
Low dose PDE5I in IC
This is a randomised, double-blind, placebo-controlled trial to evaluate the efficacy of daily low-dose sildenafil (25mg) for the treatment of non-ulcer interstitial cystitis (IC) in women. Forty-eight women with clinical diagnosis of IC, from three centres, were equally randomised to...
Reducing the burden of NMIBC: outpatient laser management in morbid patients
With non-muscle invasive bladder cancer (NMIBC) posing a significant burden on urological departments, alternative ways of safely and effectively managing these patients with a minimally invasive approach is desirable. As rates of recurrence are high but progression rates low, and...
Risk factors for BC after minimally invasive RNU
Bladder cancer (BC) after radical nephroureterectomy (RNU) has an approximate incidence of 20-50%. This contemporary multicentre study will inform the ongoing debate on risk factors for BC after minimally invasive RNU and how it may be prevented. Three hundred and...
BCG after TURBT – does timing matter?
Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...LoFric Elle Wins ‘Look Good, Feel Good’ Award
Wellspect’s revolutionary new female catheter has added another award to its list of accolades. The 'Look Good, Feel Good' award, which is a joint initiative of Bladder and Bowel UK and the...
